Moreover, d16 can inhibit HR and synergize with PARPis in several BRCA-proficient ovarian and breast cancer cells, providing a new therapeutic strategy for the treatment of TP53-mutated, BRCA1/2-WT (wild-type), breast and ovarian cancers. This evidence concerns the gene TP53 and ovarian cancer.